---
layout: post
title: "Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:35:43 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-03949
original_published: 2023-02-27 00:00:00 +0000
significance: 8.00
---

# Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** February 27, 2023 00:00 UTC
**Document Number:** 2023-03949

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment." This guidance is intended to provide recommendations to sponsors developing drugs intended to treat neovascular age-related macular degeneration focusing on eligibility criteria, trial design considerations, and efficacy endpoints to enhance clinical trial data quality and to foster greater efficiency in development programs.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/02/27/2023-03949/neovascular-age-related-macular-degeneration-developing-drugs-for-treatment-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2023-03949

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
